While ANGPT1, SKAP2, SPARC, and STAMBP were identified through MR as upstream drivers of NAFLD, the genes assessed in the Lactobacillus salivarius treatment group (SREBP1, ChREBP, ACC, and FAS) are well-characterized downstream regulators of hepatic lipid metabolism. The gene discussed is NR3C2; the disease is metabolic dysfunction-associated steatotic liver disease.